Rate My Professor David Boettiger

David Boettiger applies expertise in epidemiology and health economics to advanced analysis of large datasets and quantitative modeling addressing infectious disease challenges worldwide. His research on HIV and viral hepatitis informs clinical guidelines in Australia and internationally. Recent efforts target respiratory viruses and antimicrobial resistance prevention, detection, and management. As research lead for FluTracking, Australia's community-based surveillance for respiratory infections and a National Influenza Surveillance Program component, he integrates FluTracking with cohort studies, clinical trials, and other systems to study virus impacts and public health measures' effectiveness and cost-effectiveness. Collaborating with clinical, laboratory, and public health experts, his goal is respiratory infections that are rare, rapidly diagnosed, and treatable. Boettiger has published over 80 peer-reviewed articles, including 'Unequal access: Respiratory syncytial virus vaccine uptake by socioeconomic status among older adults in Australia' (Vaccine, 2026), 'The Pandemic REspiratory Virus Epidemiological SurveillaNce Trial - A self-swab surveillance system for respiratory viruses nested within FluTracking' (The Journal of Infectious Diseases, 2025), 'FluTracking: Weekly online community-based surveillance of respiratory illness in Australia, 2023 Report' (Communicable Diseases Intelligence, 2025), 'Disease progression & treatment need in sub-genotype C4 hepatitis B infection: a retrospective cohort study in the Northern Territory, Australia' (BMC Infectious Diseases, 2025), and 'Towards elimination of viral hepatitis B and C in Australia' (book chapter, 2025). He is Chief Investigator on NHMRC and UK-MRC grants totaling over $7.1 million.